In line with the above, S100A8 treatment significantly reduced percentages of total MDSC (CD11b+/Gr-1+), PMN-MDSC (CD11b+/Gr-1+/CD14-/F4/80-) and M-MDSC (MDSC that were CD14+ and/or F4/80+) populations in lungs from mice with LLC cancers (Total MDSC: 2.98 ± 0.90% to 0.39 ± 0.05%, p < 0.01; PMN-MDSC: 2.16 ± 0.73% to 0.36 ± 0.04%, p < 0.01; M-MDSC: 0.82 ± 0.19% to 0.03 ± 0.01%, p < 0.001) (Figures 5G–I). Here, ITGAM is linked to cancer.